Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
5 e# Y5 E3 U6 C$ O9 j I8 _: eNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 2 {3 a+ B! v+ I; h4 B# N5 F& P
+ Author Affiliations
1 H4 n/ H8 p' u6 \1 e$ ?7 L M/ s2 ^! S% j0 n/ K' d, F
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 8 J7 J7 s" y' u
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 _' Y6 a9 a# b: {
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan & z. s5 B6 f9 B' J+ c" Q5 Y' ^
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
$ G' v: a# ?% d$ g- ]7 i- u) D$ ]! Z5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
6 [& X$ j; f" G6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
) }1 D, I( s: \1 a0 w+ b$ ?, Q7Kinki University School of Medicine, Osaka 589-8511, Japan ' c1 I- _( S# M+ o4 E
8Izumi Municipal Hospital, Osaka 594-0071, Japan
: B- }! ?; o! ]: K( c4 ?( V9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
5 B; x4 l; Y7 @4 z8 ]Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp & F2 W( j% b) S E4 j/ p
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 8 J3 {2 ^7 D% T, H) w
N! x% |1 A- E! ]' M1 y
|